6505--VA Long Beach Pylarify
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
262-NETWORK CONTRACT OFFICE 22 (36C262)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36C26227Q0072
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents1
The Department of Veterans Affairs Long Beach Healthcare System, located at 5901 East 7th Street, Long Beach, California, has issued a Special Notice (Procurement Identifier: 36C26227Q0072) announcing its intent to award a sole source, firm-fixed-price contract for the supply of Pylarify (piflufolastat F18) radiopharmaceutical injections. This procurement is specifically intended to support the Nuclear Medicine department’s advanced diagnostic imaging needs, utilizing Pylarify as a PET/CT imaging agent to detect prostate-specific membrane antigen (PSMA) in tumors, lymph nodes, bones, and other organs. The use of Pylarify is critical for the accurate identification and staging of prostate cancer, thereby enhancing patient care outcomes within the VA Long Beach facility.
The scope of this procurement encompasses the delivery of Pylarify (piflufolastat F18), a specialized radiopharmaceutical manufactured by Progenics Pharmaceuticals, Inc., whose address is 331 Treble Cove Road, N. Billerica, MA 01862. The product is available under the VA National Acquisition Center Contract (NAC) Federal Supply Schedule (FSS) #36F79725D0093, with a contract period effective from April 1, 2025, through March 31, 2030. The procurement falls under the North American Industry Classification System (NAICS) code 325412, which pertains to Pharmaceutical Preparation Manufacturing, with a size standard of 1,300 employees. The Product Service Code (PSC) is 6505, indicating drugs and biologicals.
This notice is issued in accordance with Revolutionary FAR Overhaul (RFO) Part 8.401 and GSAM/R 538.7104-3(b)(ii), which allows for sole source awards when only one source is available and the items are peculiar to one manufacturer. The VA Long Beach Healthcare System has determined that Pylarify is uniquely suited to its requirements and that Progenics Pharmaceuticals is the only source capable of providing this product under the terms of the existing FSS contract.
The contracting entity responsible for this procurement is the 262-Network Contract Office 22 (36C262), a federal office within the Department of Veterans Affairs. The primary point of contact for this notice is Melissa Ramirez, Contracting Specialist, who can be reached via email at [email protected]. All inquiries and correspondence must be submitted in writing; telephone requests will not be honored.
It is important to note that this is not a solicitation for competitive quotes or proposals. The notice is for informational purposes only, and the government reserves the right to make a sole source award at its discretion. However, interested parties who believe they can provide the same items and demonstrate that competition would be advantageous to the government are invited to submit a capabilities statement. Such submissions must provide clear and compelling evidence of the ability to meet the requirements and must be received no later than November 3, 2026, at 10:00 AM Pacific Local Time. The responsibility for timely and complete transmission rests solely with the interested parties.
Contractors evaluating this opportunity should be aware that the requirement is for a highly specialized radiopharmaceutical, with strict adherence to federal supply schedule terms and sole source justification. The contract will remain constant in its scope, focusing exclusively on the supply of Pylarify for diagnostic imaging purposes within the VA Long Beach Healthcare System. For further details, the official notice and any attachments can be accessed via the SAM.gov opportunity ID d1d46e7c59d54b1281691763edad0b92.
This procurement represents a critical support activity for the VA’s ongoing commitment to advanced diagnostic care for veterans, ensuring access to state-of-the-art imaging agents for prostate cancer detection and management.